zinc finger and BTB domain containing 3Genealiases: []
Q-omics provides the consensus-scored ZBTB3 profile across patient tissues and cancer cell-line models. ZBTB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ZBTB3 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ZBTB3 RNA expression shows 20,044 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THYM, LIHC, and ACC as cancer lineages where ZBTB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB3 survival associations across molecular data types. ZBTB3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB3 RNA expression–survival associations across cancer types. High ZBTB3 expression shows unfavorable associations in ACC and LUSC, but favorable associations in THYM, HNSC, KIRP and ESCA. The THYM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for ZBTB3 RNA expression.
This table summarizes ZBTB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB3 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, HNSC, BLCA and KICH. The LIHC box plot shows higher ZBTB3 RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with ZBTB3 in patient tissues and cancer cell lines. In patient samples, ZBTB3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
